 This study has a double-blind, randomized, two-period, cross-over design. The study population will be randomized equally to the sequence 1 first 3 weeks microencapsulated Glycine, second 3 weeks placebo or sequence 2 first 3 weeks placebo, second 3 weeks microencapsulated Glycine. Study AgentPlacebo - Dosage and Route of Administration: 